Fundamental Analysis of HUMACYTE INC(NASDAQ:HUMA) stock

Fundamental Rating

HUMA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 576 industry peers in the Biotechnology industry. The financial health of HUMA is average, but there are quite some concerns on its profitability. HUMA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year HUMA has reported negative net income.

HUMA had a negative operating cash flow in the past year.

In the past 5 years HUMA always reported negative net income.

HUMA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

HUMA has a worse Return On Assets (-65.47%) than 63.00% of its industry peers.

The Return On Equity of HUMA (-404.22%) is worse than 77.14% of its industry peers.

		Industry Rank	Sector Rank
ROA	-65.47%
ROE	-404.22%
ROIC	N/A

ROA(3y)-33.83%

ROA(5y)-42.89%

ROE(3y)-283.23%

ROE(5y)-201.68%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HUMA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

HUMA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, HUMA has more shares outstanding

Compared to 1 year ago, HUMA has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.46, we must say that HUMA is in the distress zone and has some risk of bankruptcy.

HUMA has a Altman-Z score (-3.46) which is comparable to the rest of the industry.

HUMA has a Debt/Equity ratio of 0.61. This is a neutral value indicating HUMA is somewhat dependend on debt financing.

The Debt to Equity ratio of HUMA (0.61) is worse than 74.52% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF	N/A
Altman-Z	-3.46

ROIC/WACCN/A

WACC10.35%

2.3 Liquidity

A Current Ratio of 8.37 indicates that HUMA has no problem at all paying its short term obligations.

HUMA has a better Current ratio (8.37) than 70.51% of its industry peers.

HUMA has a Quick Ratio of 8.37. This indicates that HUMA is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of HUMA (8.37) is better than 70.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.37
Quick Ratio	8.37

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for HUMA have decreased strongly by -233.33% in the last year.

HUMA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

EPS 1Y (TTM)-233.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.44%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, HUMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.78% on average per year.

The Revenue is expected to grow by 464.78% on average over the next years. This is a very strong growth

EPS Next Y5.44%

EPS Next 2Y10.38%

EPS Next 3Y18.56%

EPS Next 5Y16.78%

Revenue Next Year5059.33%

Revenue Next 2Y2223.43%

Revenue Next 3Y1101.93%

Revenue Next 5Y464.78%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

HUMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

HUMA's earnings are expected to grow with 18.56% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.38%

EPS Next 3Y18.56%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for HUMA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

HUMACYTE INC

NASDAQ:HUMA (7/1/2024, 7:00:02 PM)

After market: 5.44 +0.07 (+1.3%)

5.37

+0.57 (+11.88%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap639.46M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-65.47%
ROE	-404.22%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.61
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8.37
Quick Ratio	8.37
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-233.33%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y5.44%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

HUMACYTE INC (HUMA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens